Savinelli equally contributed to this study.Abbreviations: 5-An, 5-aminonicotinic acid; AMPA, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid hydrate; CBIO, 6-chloro-1,2-benzisoxazol-3(2H)-one; DAAO, d-amino acid oxidase; DASPO or DDO, d-aspartate oxidase; DPPD, pyrido[2,3-b]pyrazine-2,3(1H,4H)-dione; EMTN, enzyme monitored turnover; hDAAO, human d-amino acid oxidase; hDASPO, human d-aspartate oxidase; IAsp, iminoaspartate; MT, meso-tartrate; NMDAR, N-methyl-d-aspartate receptor; OA, oxaloacetate; RgDAAO, d-amino acid oxidase from Rhodotorula gracilis. Abstract d-Amino acids are the "wrong" enantiomers of amino acids as they are not used in proteins synthesis but evolved in selected functions. On this side, d-aspartate (d-Asp) plays several significant roles in mammals, especially as an agonist of N-methyl-daspartate receptors (NMDAR), and is involved in relevant diseases, such as schizophrenia and Alzheimer's disease. In vivo modulation of d-Asp levels represents an intriguing task to cope with such pathological states. As little is known about d-Asp synthesis, the only option for modulating the levels is via degradation, which is due to the flavoenzyme d-aspartate oxidase (DASPO). Here we present the first threedimensional structure of a DASPO enzyme (from human) which belongs to the damino acid oxidase family. Notably, human DASPO differs from human d-amino acid oxidase (attributed to d-serine degradation, the main coagonist of NMDAR)showing peculiar structural features (a specific active site charge distribution), oligomeric state and kinetic mechanism, and a higher FAD affinity and activity. These results provide useful insights into the structure-function relationships of human DASPO: modulating its activity represents now a feasible novel therapeutic target.
K E Y W O R D Sd-aspartate, d-aspartate oxidase, flavoprotein, NMDA receptor, structure-function relationships